<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473431</url>
  </required_header>
  <id_info>
    <org_study_id>IMexicanoSS</org_study_id>
    <nct_id>NCT03473431</nct_id>
  </id_info>
  <brief_title>Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.</brief_title>
  <official_title>A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the prevalence of depression in elderly is from 4 to 30% and is associated with a lower
      quality of life mayor medical comorbidity, and increased mortality. Although there are
      various treatments for depression in the elderly, the study of interventions in resistant
      depression is limited and there are few reports of the efficacy and safety profile of
      alternative interventions such as ketamine in the elderly. The final objective of the present
      study is to report the effects of a single infusion of ketamine on the depressive symptoms in
      patients undergoing ophthalmologic surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The final objective of the present study is to report the effects of a single infusion of 0.5
      mg / kg ketamine in infusion on depressive symptoms assessed using the scale Yesavage's
      abbreviated Geriatric Depression Scale.

      This is a randomized double-blind follow-up study in patients over 60 years of age with
      ocular pathology who required ophthalmological surgery with retrobulbar block and conscious
      sedation with ketamine. The sample consisted of two groups: a control group and an
      experimental group with ketamine. The dose used for the study was 0.5mg / kg in slow infusion
      for two hours. In both groups the Yesavage's questionnaire was applied at three different
      times; Basally, at the end of the recovery and at 24 hours after the surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, dose-controlled follow-up study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>two hours and 24 hours after the ketamine infusion</time_frame>
    <description>change in score in scale Yesavage's abbreviated Geriatric Depression Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression rate</measure>
    <time_frame>two hours and 24 hours after the ketamine infusion</time_frame>
    <description>change in the percentage of patients with criteria for depression based on cutting point of 5 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Depression in Old Age</condition>
  <condition>Ketamine</condition>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single infusion of 0.5 mg / kg ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>physiological solution at 0.9 % with the same physical characteristics of ketamine solution,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>single infusion of 0.5 mg / kg ketamine</description>
    <arm_group_label>ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>physiological solution at 0.9 % with the same physical characteristics of ketamine solution,</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 60 years or older who due to the severity of visual disability
             required to be operated on for eye surgery using retrobulbar block

          -  Intraocular pressure &lt;20 mm Hg and

          -  ASA functional capacity from I to III

        Exclusion Criteria:

          -  Previous antidepressants medications

          -  Cognitive impairment was found according to the Short Portable Mental Status
             Questionnaire (SPMSQ) assessment

          -  In case of a history of psychosis, schizophrenia, nephropathy

          -  They had a history of difficulties to control arterial blood pressure, uncontrolled
             hepatic disorders or had a history of adverse response to ketamine according clinical
             records
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DULCE RASCON MARTINEZ, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>imss</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DULCE RASCON MARTINEZ, M.D</last_name>
    <phone>+52 (55) 56276900</phone>
    <phone_ext>21607</phone_ext>
    <email>drarascon@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DULCE RASCON MARTINEZ</last_name>
    <phone>+52 (55) 56276900</phone>
    <phone_ext>21607</phone_ext>
    <email>drarascon@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. J Clin Psychiatry. 2017 Apr;78(4):e415-e419. doi: 10.4088/JCP.17f11567. Review.</citation>
    <PMID>28448702</PMID>
  </reference>
  <reference>
    <citation>Arandjelovic K, Eyre HA, Lavretsky H. Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports. Am J Geriatr Psychiatry. 2016 Oct;24(10):913-7. doi: 10.1016/j.jagp.2016.05.010. Epub 2016 May 18.</citation>
    <PMID>27591914</PMID>
  </reference>
  <reference>
    <citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.</citation>
    <PMID>10686270</PMID>
  </reference>
  <reference>
    <citation>Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS; Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ. Grand challenges in global mental health. Nature. 2011 Jul 6;475(7354):27-30. doi: 10.1038/475027a.</citation>
    <PMID>21734685</PMID>
  </reference>
  <reference>
    <citation>Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20. Review.</citation>
    <PMID>25038867</PMID>
  </reference>
  <reference>
    <citation>George D, Gálvez V, Martin D, Kumar D, Leyden J, Hadzi-Pavlovic D, Harper S, Brodaty H, Glue P, Taylor R, Mitchell PB, Loo CK. Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. Am J Geriatr Psychiatry. 2017 Nov;25(11):1199-1209. doi: 10.1016/j.jagp.2017.06.007. Epub 2017 Jun 13.</citation>
    <PMID>28739263</PMID>
  </reference>
  <reference>
    <citation>Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, Li P, Zhou X, Zhang Y, Liu Y, Xie P. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016 Nov 3;12:2859-2867. eCollection 2016.</citation>
    <PMID>27843321</PMID>
  </reference>
  <reference>
    <citation>Martinez de la Iglesia, J., Onis Vilches Ma, C., Duenas Herrero, R., Albert Colomer, C., Aguado Taberne, C., &amp; Luque Luque, R. (2002). The Spanish version of the Yesavage abbreviated questionnaire (GDS) to screen depressive dysfunctions in patients older than 65 years. [Spanish]. MEDIFAM - Revista de Medicina Familiar Y Comunitaria, 12(10), 620-630</citation>
  </reference>
  <reference>
    <citation>Stek ML, Vinkers DJ, Gussekloo J, van der Mast RC, Beekman AT, Westendorp RG. Natural history of depression in the oldest old: population-based prospective study. Br J Psychiatry. 2006 Jan;188:65-9.</citation>
    <PMID>16388072</PMID>
  </reference>
  <reference>
    <citation>Volkert J, Schulz H, Härter M, Wlodarczyk O, Andreas S. The prevalence of mental disorders in older people in Western countries - a meta-analysis. Ageing Res Rev. 2013 Jan;12(1):339-53. doi: 10.1016/j.arr.2012.09.004. Epub 2012 Sep 19. Review.</citation>
    <PMID>23000171</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>Dulce Maria Rascon Martinez</investigator_full_name>
    <investigator_title>MD Clinical Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

